GT19870

GT19870 is an orally bioavailable molecular glue degrader (MGD) developed by Kintor Pharmaceutical Limited. It acts by targeting the G1 to S phase transition protein 1 (GSPT1) as a neo-substrate, which subsequently leads to the degradation of the oncogenic transcription factors c-Myc and n-Myc. These Myc proteins are critical drivers in various hematological and solid tumors but have historically been difficult to target directly. Preclinical studies have shown that GT19870 effectively inhibits cell proliferation and induces tumor regression in models of acute myeloid leukemia (AML), small cell lung cancer (SCLC), castration-resistant prostate cancer (mCRPC), and neuroblastoma. The compound is currently in the IND-enabling stage of development.